Currently out of the existing stock ratings of Difei Yang, 176 are a BUY (88.44%), 21 are a HOLD (10.55%), 2 are a SELL (1.01%).

Difei Yang

Work Performance Price Targets & Ratings Chart

Analyst Difei Yang, currently employed carries an average stock price target met ratio of 48.53% that have a potential upside of 45.37% achieved within 277 days. Previously, Difei Yang worked at MIZUHO.

Difei Yang’s has documented 419 price targets and ratings displayed on 29 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 24-Jun-2022.

Wall Street Analyst Difei Yang

Analyst best performing recommendations are on RLYP (RELYPSA).
The best stock recommendation documented was for RLYP (RELYPSA) at 7/18/2016. The price target of $26 was fulfilled within 3 days with a profit of $5.75 (28.4%) receiving and performance score of 94.65.

Average potential price target upside

of $81.89 (107.07%) on SRPT (SAREPTA THERAPEUTICS).
of $37.8 (70.98%) on PTX (PERNIX THERAPEUTICS HOLDINGS).
of $18.95 (34.03%) on ONCE (SPARK THERAPEUTICS).

AERI Aerie Pharmaceuticals . AKBA Akebia Ther BLUE Bluebird bio CNCE Concert Pharmaceuticals FGEN FibroGen FRLN Freeline Therapeutics Holdings Plc HZNP Horizon Pharma PLC MNTA Momenta Pharmaceuticals NKTR Nektar Therapeutics NVCR Novocure Ltd RLYP Relypsa RVNC Revance The SELB Selecta Biosciences SRPT Sarepta Therapeutics XERS Xeris Pharmaceuticals ZGNX Zogenix MGTA Magenta Therapeutics ONCE Spark Therapeutics PTX Pernix Therapeutics Holdings AVRO AVROBIO HRTX Heron Therapeuti ALDR Alder BioPharmaceuticals BOLD Audentes Therapeutics EOLS Evolus ABEO Abeona Therapeutics AKAO Achaogen MRNS Marinus Pharmaceuticals VNDA Vanda Pharmaceuticals QURE Uniqure NV

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Yigal Nochomovitz (CITI)